Ben & Jerry's Co-Founders Not Worried About Ozempic's Impact On Ice Cream Business: Here's Why
Portfolio Pulse from Benzinga Neuro
Ben & Jerry's co-founders are not concerned about the impact of weight-loss drugs on their ice cream business, despite Unilever's plans to spin off its ice cream division. They believe ice cream is more about enjoyment than nutrition. Meanwhile, companies like Eli Lilly and Novo Nordisk are seeing increased demand for weight-loss drugs.
June 27, 2024 | 5:38 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Eli Lilly is seeing increased demand for its weight-loss drugs like Ozempic, which could impact the food and beverage industry, including ice cream consumption.
The growing demand for Eli Lilly's weight-loss drugs could lead to a shift in consumer behavior, potentially reducing ice cream consumption. This could positively impact Eli Lilly's stock as the market for weight-loss drugs expands.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 60
POSITIVE IMPACT
Novo Nordisk is expanding its U.S. manufacturing operations to meet the surging demand for its weight-loss drugs, reflecting the growing market for GLP-1 medications.
Novo Nordisk's investment in expanding its manufacturing operations indicates strong demand for its weight-loss drugs. This expansion could drive revenue growth and positively impact the stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 60
NEUTRAL IMPACT
Unilever plans to spin off its ice cream division, including Ben & Jerry's. Despite concerns about weight-loss drugs, Ben & Jerry's has shown stronger sales growth than Unilever's broader ice cream business.
Unilever's spin-off plans for its ice cream division could lead to changes in the company's structure and focus. However, Ben & Jerry's strong sales growth may mitigate concerns about the impact of weight-loss drugs.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80